Evidence map›Paper›PMID 38969782›Full record

ArticleNature materials2024

Synthetic extremophiles via species-specific formulations improve microbial therapeutics.

Miguel Jimenez, Johanna L'Heureux, Emily Kolaya, Gary W Liu, Kyle B Martin, Husna Ellis, Alfred Dao, Margaret Yang, Zachary Villaverde, Afeefah Khazi-Syed and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miguel JimenezDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4211-1852
Johanna L'HeureuxDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-0261-196X
Emily KolayaDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0009-0121-1209
Gary W LiuDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kyle B MartinDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Husna EllisDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Alfred DaoDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Margaret YangDepartment of Chemistry and Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Zachary VillaverdeDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Afeefah Khazi-SyedDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-0799-965X
Qinhao CaoDepartment of Chemistry and Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5948-8934
Niora FabianDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Joshua JenkinsDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nina FitzgeraldDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Christina KaravasiliDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8648-1444
Benjamin MullerDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
James D ByrneDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Giovanni TraversoDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.ORCID 0000-0001-7851-4077

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Novel extremophile-inspired radioprotectantsDP2CA301081 · NCI · UNIVERSITY OF IOWA · PI BYRNE, JAMES DONALD · 2024 to 2024
$1.4M
Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal BowelK08CA276908 · NCI · UNIVERSITY OF IOWA · PI James Donald Byrne · 2023 to 2026
$1.0M
National Aeronautics and Space Administration (NASA) NNX16AO69ANCI NIH HHS DP2 CA301081NCI NIH HHS K08 CA276908United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) FA8650-21-2-7120
6 · The paper itself

Abstract

Microorganisms typically used to produce food and pharmaceuticals are now being explored as medicines and agricultural supplements. However, maintaining high viability from manufacturing until use remains an important challenge, requiring sophisticated cold chains and packaging. Here we report synthetic extremophiles of industrially relevant gram-negative bacteria (Escherichia coli Nissle 1917, Ensifer meliloti), gram-positive bacteria (Lactobacillus plantarum) and yeast (Saccharomyces boulardii). We develop a high-throughput pipeline to define species-specific materials that enable survival through drying, elevated temperatures, organic solvents and ionizing radiation. Using this pipeline, we enhance the stability of E. coli Nissle 1917 by more than four orders of magnitude over commercial formulations and demonstrate its capacity to remain viable while undergoing tableting and pharmaceutical processing. We further show, in live animals and plants, that synthetic extremophiles remain functional against enteric pathogens and as nitrogen-fixing plant supplements even after exposure to elevated temperatures. This synthetic, material-based stabilization enhances our capacity to apply microorganisms in extreme environments on Earth and potentially during exploratory space travel.

Indexed as

ExtremophilesAnimalsEscherichia coliSpecies Specificity

Identifiers

PMID38969782
PMCPMC11840811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.